Ind-Swift Laboratories Limited (INDSWFTLAB) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE915B01019
Key metrics
- Market Cap
- ₹3,190 Cr
- P/E Ratio
- 56.27
- EPS
- 6.49
- Book Value
- 159.38
- P/B Ratio
- 2.28
- ROE
- 2.99%
- ROCE
- 1.03%
- Debt / Equity
- 0.01
- Net Margin
- 6.46%
- Revenue Growth
- 11.68%
- Profit Growth
- -83.47%
- Dividend Yield
- —
- 52W High
- ₹389.50
- 52W Low
- ₹87.15
- Market Cap Band
- small cap
- Face Value
- 10
Ratios computed from the annual results period ending 2026-03-31.
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is based in Manimajra, India.
- Headquarters
- Manimajra, India
- Promoter Holding
- 63.73%
The full Ind-Swift Laboratories Limited analysis
Create a free account to open the complete INDSWFTLAB deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.